MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for alleged violations of the Securities Exchange Act of 1934 [1][2] - The lawsuit claims that MoonLake made false and misleading statements regarding its drug sonelokimab, asserting it was superior to competitors without evidence [2] - The Phase 3 trial results released by the company were deemed "disastrous" by analysts, indicating that public statements were materially misleading [2] Class Action Details - The class period for the lawsuit is from March 10, 2024, to September 29, 2025 [2] - Shareholders who purchased shares during this period are encouraged to contact the law firm for potential lead plaintiff appointments [2][3] - The deadline for filing claims is December 15, 2025 [2] Law Firm Information - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns [4] - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims [4]